Conflicting Signals on Timeline of New EU Pharmaceutical Legislation

Recent updates from internal EU coordination meetings point to inconsistent messaging by European authorities regarding the implementation timeline of the new pharmaceutical legislation.

Public communications so far have consistently stated that the legislation would take effect 18 to 36 months after publication in the EU Official Journal. This timeframe has been widely cited in presentations, stakeholder briefings, and industry conferences.

However, minutes from a recent meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) indicate a staggered application model. According to the document, the “Union List of Critical Medicines” will apply immediately upon entry into force. Chapter X, covering availability and security of supply, will become applicable six months later, with additional provisions phased in subsequently.

While phased implementation is common in EU law, the contrast between earlier public messaging and internal discussions has created uncertainty. The absence of a consolidated final legal text further complicates planning for companies, regulators, and supply chain stakeholders.

16-02-2026